导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.22% | 2139/4773 |
| 近一周 | -2.26% | 1614/5462 |
| 近一月 | -5.63% | 3296/5421 |
| 近一季 | -13.12% | 3946/5209 |
| 近半年 | -7.40% | 3213/4920 |
| 近一年 | 3.92% | 1828/4366 |
| 近两年 | 77.72% | 841/2954 |
| 近三年 | 35.94% | 836/2253 |
| 成立以来 | 139.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.47% 1535/4961 |
20.45% 1225/5312 |
- - |
- - |
| 2025 | 30.51% 1312/4813 |
3.65% 1058/3635 |
2.32% 1653/4076 |
22.02% 1713/4524 |
0.85% 1719/4813 |
| 2024 | 6.41% 1758/3463 |
-5.79% 1951/2808 |
-8.31% 2214/3014 |
17.52% 1172/3129 |
4.83% 665/3463 |
| 2023 | -3.76% 649/2656 |
10.49% 365/2280 |
-2.47% 597/2385 |
-7.72% 1614/2515 |
-3.21% 631/2655 |
| 2022 | -22.64% 1079/2207 |
-18.00% 1289/1919 |
4.19% 1040/2016 |
-12.52% 720/2113 |
3.51% 681/2208 |
| 2021 | 16.01% 285/1822 |
-4.78% 887/1255 |
12.75% 312/1330 |
-0.13% 479/1466 |
8.20% 160/1822 |
| 2020 | 28.82% 552/1250 |
-1.11% 203/1028 |
21.03% 251/1067 |
5.07% 929/1164 |
2.44% 986/1184 |
| 2019 | 30.54% 482/1092 |
31.36% 204/754 |
-11.16% 763/804 |
3.27% 261/850 |
8.30% 328/918 |
| 2018 | -33.94% 560/834 |
- - |
- - |
- - |
-11.84% 363/691 |
| 2017 | -12.00% 548/714 |
- - |
- - |
- - |
- - |
| 2016 | -20.57% 445/605 |
- - |
- - |
- - |
- - |
| 2015 | 56.42% 10/575 |
- - |
- - |
- - |
- - |
| 2014 | 20.40% 192/237 |
- - |
- - |
- - |
- - |
| 2013 | 38.86% 7/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实中创400ETF联接A VS. 长安沪深300非周期A(740101) |